Translation in solid cancer: are size‐based response criteria an anachronism?

Clinical and Translational Oncology

Volumn 17, Issue 1, 2015, Pages

  Fernandes, M ^a   Rosel, D ^b   Brabek J ^b  

^a Medbase   (United States)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Desmoplasia; Imaging; Immune checkpoint inhibitors; Invadopodia; Metastasis; RECIST; Solid cancer; Stroma; Translation; Tyrosine kinase inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT;

HUMAN; METASTASIS; NEOPLASMS; ONCOLOGY; PROCEDURES; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TRENDS; TUMOR INVASION; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; HUMANS; MEDICAL ONCOLOGY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84939877182     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-014-1207-5     Document Type: Review

References (96)

1. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013;501:338–45.
2. Turner NC, Reis-Filho JS. Genetic heterogeneity and cancer drug resistance. Lancet Oncol. 2012;13:178–85.
3. Janku F. Tumor heterogeneity in the clinic: is it a real problem? Ther Adv Med Oncol. 2014;6:43–51.
4. Logue JS, Morrison DK. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012;26:641–50.
5. Lovly CM, Shaw AT. Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res. 2014;20:2249–56.
6. DeVita VT, Rosenberg SA. Two hundred years of cancer research. N Engl J Med. 2012;366:2207–14.
7. Rösel D, Brábek J, Veselý P, Fernandes M. Drugs for solid cancer: the productivity crisis prompts a rethink. Onco Targets Ther. 2013;6:767–77.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
9. Olson P, Hanahan D. Breaching the cancer fortress. Science. 2009;324:1400–1.
10. Micke P, Östman A. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets. 2005;9:1217–33.
11. Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res. 2014;12:297–312.
12. Fearon DT. The carcinoma-associated fibroblast expressing fibroblast activation protein and escape from immune surveillance. Cancer Immunol Res. 2014;2:1–7.
13. Tchou J, Conejo-Garcia J. Targeting the tumor stroma as a novel treatment strategy for breast cancer: shifting from the neoplastic cell-centric to a stroma-centric paradigm. Adv Pharmacol. 2012;65:45–61.
14. Zhang J, Liu J. Tumor stroma as targets for cancer therapy. Pharmacol Ther. 2013;137:200–15.
15. Sounni NE, Noel A. Targeting the tumor microenvironment for cancer therapy. Clin Chem. 2013;59:85–93.
16. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev. 2012;92:897–965.
17. Mountz JM, Yankeelov TE, Rubin DL, Buatti JM, Erikson BJ, Fennessy FM, et al. Letter to cancer center directors: progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. J Clin Oncol 2014;32(19):2115–6
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
19. Ganten MK, Ganten TM, Schlemmer HP. Radiological monitoring of the treatment of solid tumors in practice. Rofo. 2014;186:466–73.
20. Najjar YG, Rini BI. Novel agents in renal carcinoma: a reality check. Ther Adv Med Oncol. 2012;4:183–94.
21. Fabbro D, Cowan-Jacob SW, Möbitz H, Martiny-Baron G. Targeting cancer with small-molecular-weight kinase inhibitors. Methods Mol Biol. 2012;795:1–34.
22. Ocaña A, Amir E, Seruga B, Martin M, Pandiella A. The evolving landscape of protein kinases in breast cancer: clinical implications. Cancer Treat Rev. 2013;39:68–76.
23. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS Lett. 2014;588:368–76.
24. Sliwkowski MX, Mellman I. Antibody therapeutics in cancer. Science. 2013;341:1192–8.
25. Diederich S. Imaging beyond RECIST: CT and MRI in molecular therapies. Cancer Imaging. 2012;12:347–50.
26. Coche E. Recist and beyond. JBR-BTR. 2013;96:167–71.
27. Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, et al. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013;79:283–8.
28. Liu Y, Litière S, de Vries EG, Sargent D, Shankar L, Bogaerts J, et al. The role of response evaluation criteria in solid tumour in anticancer treatment evaluation: results of a survey in the oncology community. Eur J Cancer. 2014;50:260–6.
29. Bensch F, van Kruchten M, Lamberts LE, Schröder CP, Hospers GA, Brouwers GH, et al. Molecular imaging for monitoring treatment response in breast cancer patients. Eur J Pharmacol. 2013;717(1–3):2–11.
30. Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–20.
31. Ribas A, Chmielowski B, Glaspy JA. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009;15:7116–8.
32. Mattern J, Volm M. Imbalance of cell proliferation and apoptosis during progression of lung carcinomas. Anticancer Res. 2004;24:4243–6.
33. Cousin S, Taieb S, Penel N. A paradigm shift in tumour response evaluation of targeted therapy: the assessment of novel drugs in exploratory clinical trials. Curr Opin Oncol. 2012;24:338–44.
34. Gao MQ, Kim BG, Kang S, Kim BG, Kang S, Kim SH, et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci. 2010;123(Pt 20):3507–14.
35. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive growth. Int J Cancer. 2008;123:2229–38.
36. Räsänen K, Vaheri A. Activation of fibroblasts in cancer stroma. Exp Cell Res. 2010;316:2713–22.
37. Bremnes RM, Dønnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, et al. The role of tumor stroma in cancer progression and prognosis. Emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol. 2011;6:209–17.
38. Strell C, Rundqvist H, Östman A. Fibroblasts—a key host cell type in tumor initiation, progression, and metastasis. Ups J Med Sci. 2012;117:187–95.
39. Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J Cell Sci. 2012;125(Pt 23):5591–6.
40. Goruppi S, Dotto GP. Mesenchymal stroma: primary determinant and therapeutic target for epithelial cancer. Trends Cell Biol. 2013;23:593–602.
41. Tripathi M, Billet S, Bhowmick NA. Understanding the role of stromal fibroblasts in cancer progression. Call Adh Migr. 2012;6:231–5.
42. Sleeman JP. The metastatic niche and stromal progression. Cancer Metastasis Rev. 2012;31:429–40.
43. Sleeman JP, Christofori G, Fodde R, Collard JG, Berx G, Decraene C, et al. Concepts of metastasis in flux: the stromal progression model. Semin Cancer Biol. 2012;22:174–86.
44. Waghray M, Yalamanchili M, di Magliano MP, Simeone DM. Deciphering the role of stroma in pancreatic cancer. Curr Opin Gastroenterol. 2013;29:537–43.
45. Neesse A, Krug S, Gress TM, Tuveson DA, Michl P. Emerging concepts in pancreatic cancer medicine: targeting the tumor stroma. Onco Targets Ther. 2014;7:33–43.
46. Tolde O, Rosel D, Vesely P, Folk P, Brábek J. The structure of invadopodia in a complex 3D environment. Eur J Cell Biol. 2010;89(9):674–80.
47. Destaing O, Block MR, Planus E, Albiges-Rizo C. Invadosome regulation by adhesion signaling. Curr Opin Cell Biol. 2011;23(5):597–606.
48. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK–p130Cas complex. J Cell Biol. 2012;196(3):375–85.
49. Brentnall TA. Arousal of cancer-associated stromal fibroblasts: palladin-activated fibroblasts promote tumor invasion. Cell Adh Migr. 2012;6:488–94.
50. Goicoechea SM, García-Mata R, Staub J, Valdivia A, Sharek L, McCulloch CG, et al. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene. 2014;33:1265–73.
51. Allen M, Louise Jones J. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223:163–77.
52. Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 2013;228:1651–7.
53. Mehner C, Radisky DC. Triggering the landslide: the tumor-promotional effects of myofibroblasts. Exp Cell Res. 2013;319:1657–62.
54. Cirri P, Chiarugi P. Cancer-associated-fibroblasts and tumour cells: a diabolic liaison driving cancer progression. Cancer Metastasis Rev. 2012;31:195–208.
55. Desar IM, van Herpen CM, van Laarhoven HW, Barentsz JO, Oyen WJ, van der Graaf WT. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy. Cancer Treat Rev. 2009;35:309–21.
56. Narunsky L, Oren R, Bochner F, Neeman M. Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol Ther. 2014;141:192–208.
57. Garcia Figuerias R, Padhani AR, Goh VJ, Vilanova JC, González SB, Martín CV, et al. Novel oncologic drugs: what they do and how they affect images. Radiographics. 2011;31:2059–91.
58. Kang H, Lee HY, Lee KS, Kim JH. Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol. 2012;13:371–90.
59. Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, et al. Promise and pitfalls of quantitative imaging in oncology clinical trials. Magn Reson Imaging. 2012;30:1301–12.
60. Sullivan DC, Gatsonis C. Response to treatment series: part 1 and introduction, measuring tumor response—challenges in the era of molecular medicine. Am J Roentgenol. 2011;197:15–7.
61. Rezai P, Pisaneschi MJ, Feng C, Yaghmai V. A radiologist’s guide to treatment response criteria in oncologic imaging: functional, molecular, and disease-specific imaging biomarkers. Am J Roentgenol. 2013;201:246–56.
62. Tirkes T, Hollar MA, Tann M, Kohli MD, Akisik F, Sandrasegaran K. Response criteria in oncologic imaging: review of traditional and new criteria. Radiographics. 2013;33:1323–41.
63. Winnard PT Jr, Pathak AP, Dhara S, Cho SY, Raman V, Pomper MG. Molecular imaging of metastatic potential. J Nucl Med. 2008;49(Suppl 2):96S–112S.
64. Fein MR, Egeblad M. Caught in the act: revealing the metastatic process by live imaging. Dis Model Mech. 2013;6:580–93.
65. Lok C. Cancer caught in the act. Nature. 2014;509:148–9.
66. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer. 2010;46:1177–80.
67. Elvin P, Garner AP. Tumour invasion and metastasis: challenges facing drug discovery. Curr Opin Pharmacol. 2005;5:374–81.
68. Bidard F-C, Pierga J-Y, Soria J-C, Thiery JP. Translating metastasis-related biomarkers to the clinic—progress and pitfalls. Nat Rev Clin Oncol. 2013;10:169–79.
69. Weber GF. Why does cancer therapy lack effective anti-metastasis drugs? Cancer Lett. 2013;328:207–11.
70. Kuhn TS. The structure of scientific revolutions: 50th Anniversary edition. Chicago: University of Chicago Press; 2012.
71. Drake CG, Lipson EJ, Brahmer JR. Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nat Rev Clin Oncol. 2014;11:24–37.
72. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
73. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. Nat Rev Cancer. 2012;12:540–52.
74. Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54.
75. Hoos A, Eggermont AMM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst. 2010;102:1388–97.
76. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med. 2011;9:214.
77. Curran SD, Muellner AU, Schwartz LH. Imaging response assessment in oncology. Cancer Imaging. 2006;6:S126–30.
78. Tunariu N, Kaye SB, Desouza NM. Functional imaging: what evidence is there for its utility in clinical trials of targeted therapies? Br J Cancer. 2012;106:619–28.
79. Mankoff DA, Pryma DA, Clark AS. Molecular imaging biomarkers for oncology clinical trials. J Nucl Med. 2014;55:525–8.
80. Kadaba R, Birke H, Wang J, Hooper S, Andl CD, Di Maggio F, et al. Imbalance of desmoplastic stromal cell numbers drives aggressive cancer processes. J Pathol. 2013;230:107–17.
81. León L, García-Figueras R, Suárez C, Arjonilla A, Puente J, Vargas B, et al. Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. Target Oncol. 2014;9:9–24.
82. Rasmussen F. Metastatic renal cell cancer. Cancer Imaging. 2013;13:374–80.
83. Bex A, Fournier L, Lassau N, Mulders P, Nathan P, Oyen WJ, et al. Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. Eur Urol. 2014;65:766–77.
84. Kekelidze M, D’Errico L, Pansini M, Tyndall A, Hohmann J. Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol. 2013;19:8502–14.
85. Nishino M, Hatabu H, Johnson BE, McLoud TC. State of the art: response assessment in lung cancer in the era of genomic medicine. Radiology. 2014;271:6–27.
86. Kostakoglu L, Cheson BD. State-of-the-art research on lymphomas: role of molecular imaging for staging, prognostic evaluation, and treatment response. Front Oncol. 2013;3:212.
87. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008;452:580–9.
88. Murphy P, Koh DM. Imaging in clinical trials. Cancer Imaging. 2010;10(Spec no A):S74–82.
89. Johnson JR, Ning Y-M, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst. 2011;103:636–44.
90. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014;110:551–5.
91. Kocher R, Roberts B. The calculus of cures. N Engl J Med. 2014;370:1473–5.
92. Serkova NJ. Translational imaging endpoints to predict treatment response to novel targeted anticancer agents. Drug Resist Updat. 2011;14:224–35.
93. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933–80.
94. Ramsey SD, Ganz PA, Shankaran V, Peppercorn J, Emanuel E. Addressing the American health-care cost crisis: role of the oncology community. J Natl Cancer Inst. 2013;105:1777–81.
95. Brábek J, Fernandes M. Affordable cancer care. Lancet Oncol. 2012;13:2–3.
96. Brábek J, Fernandes M. Opinion: reasons for the R&D crisis. The scientist, 2013. http://www.the-scientist.com/?articles.view/articleNo/37522/title/Opinion--Reasons-for-the-R-D-Crisis/.